<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192410</url>
  </required_header>
  <id_info>
    <org_study_id>Alpha Omega Cohort</org_study_id>
    <nct_id>NCT03192410</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)</brief_title>
  <official_title>Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch
      patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years
      before enrolment. During the first 40 months of follow-up, patients took part in an
      experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov
      NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet,
      lifestyle and other factors were collected by means of questionnaires. Patients were
      physically examined by trained research nurses and blood samples were obtained. Follow-up for
      vital status and cause-specific mortality is ongoing. The trial was approved by a central
      medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients
      provided written informed consent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Details are reported in publications.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2002</start_date>
  <completion_date type="Anticipated">January 2040</completion_date>
  <primary_completion_date type="Anticipated">January 2040</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) through study completion</time_frame>
    <description>Death from cardiovascular disease, obtained from causes of death register of Statistics Netherlands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) through study completion</time_frame>
    <description>Vital status obtained from municipal population registers in the Netherlands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Incidence of fatal and nonfatal cardiovascular events and hospitalisations for cardiac interventions, based on verified information from GP records, hospital records and mortality registers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary heart disease</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) through study completion</time_frame>
    <description>Incidence of fatal and non-fatal coronary heart disease, based on verified information from GP records, hospital records and mortality registers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) through study completion</time_frame>
    <description>Incidence of fatal and non-fatal stroke, based on verified information from GP records, hospital records and mortality registers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiovascular mortality</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) through study completion</time_frame>
    <description>Death from cancer or other non-cardiovascular causes, obtained from causes of death register of Statistics Netherlands</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type 2 diabetes</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Incidence of type 2 diabetes, on basis of self-reported physician diagnosis, use of antidiabetic drugs, or elevated blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in serum cystatin C-based estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in global cognitive function, based on Mini Mental State Examination (MMSE) score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>After 40 months of follow-up</time_frame>
    <description>Score on 15-item Geriatric Depression Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Dispositional optimism</measure>
    <time_frame>After 40 months of follow-up</time_frame>
    <description>Scores on a 4-item questionnaire and the (revised) Life Orientation Test (LOT-R)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in body weight, assessed by trained research nurses</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in office blood pressure, assessed by trained research nurses</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipids</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in non-fasting serum total, LDL and HDL cholesterol, assessed by standard laboratory methods</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in non-fasting plasma glucose, insulin and HbA1C, assessed by standard laboratory methods</description>
  </other_outcome>
  <other_outcome>
    <measure>DNA genotype</measure>
    <time_frame>At baseline (2002-2006)</time_frame>
    <description>DNA genotype, assessed by Global Screening Array (Illumina, Inc.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers of Inflammation</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in blood biomarkers of inflammation, assessed by MesoScale assays</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical markers of endothelial function</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in blood biomarkers of endothelial function, assessed by MesoScale assays</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers of cardiac function</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in blood biomarkers of cardiac function (e.g, NT-proBNP, troponin), assessed by chemiluminescence</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers of kidney function</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in blood biomarkers of kidney function, assessed by immunoassay</description>
  </other_outcome>
  <other_outcome>
    <measure>Prostate-specific antigen (PSA)</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in blood total PSA concentration, assessed by immunometric assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Testosterone</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in serum testosterone concentration, assessed by immunoassay</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating fatty acids</measure>
    <time_frame>From entry into the study (baseline: 2002-2006) until November 2009</time_frame>
    <description>Change in concentration of fatty acids (percent weight) in plasma cholesteryl esters</description>
  </other_outcome>
  <enrollment type="Actual">4837</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Mortality</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cognitive Decline</condition>
  <condition>Mental Well-being</condition>
  <condition>Kidney Function</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary intake</intervention_name>
    <description>Intake of nutrients, foods, food groups, beverages; dietary patterns.</description>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle factors</intervention_name>
    <description>Physical activity; smoking; alcohol use; educational level.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood biomarkers</intervention_name>
    <description>Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Health</intervention_name>
    <description>Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA</intervention_name>
    <description>SNPs (GWAS)</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mental well-being</intervention_name>
    <description>Cognitive function; dispositional optimism; depression.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Non-fasting venous blood samples were taken in 4785 patients at baseline, in 810 patients
      after 20 months and in 2503 patients after 40 months of follow-up. DNA has been extracted for
      genotyping.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        4837 patients (78% male) with a history of myocardial infarction up to 10 y before entry
        into the study, recruited from 32 hospitals in the Netherlands.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The Alpha Omega Cohort is a prospective cohort study. The cohort originated from the Alpha
        Omega Trial, a 40-month intervention study of low doses of n-3 fatty acids (in margarine
        spreads) and cardiovascular events (NCT00127452). The in/exclusion criteria were defined
        for the Alpha Omega Trial.

        Inclusion criteria:

          -  Men and women

          -  Aged 60 through 80 y

          -  Verified clinically diagnosed myocardial infarction up to 10 y before entry into the
             study

          -  Written informed consent

        Exclusion criteria:

          -  Living in a nursing home or other institution

          -  Participation in another scientific study

          -  Habitual margarine intake &lt; 10 g per day

          -  Habitual fish intake &gt; 150 g per day

          -  Habitual alcohol intake &gt; 6 drinks per day

          -  Use of fish oil capsules or other supplements containing omega-3 fatty acids

          -  Presence of cancer with &lt; 1 y of life expectancy

          -  Cognitive impairment, as indicated by the Mini Mental State Examination (score &lt;= 21)

          -  Unintended weight loss &gt; 5 kg in the past year

          -  Lack of facilities for cooled margarine storage at home

          -  Inability or unwillingness to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna M Geleijnse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University, Division of Human Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <zip>6700 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.alphaomegatrial.com</url>
    <description>Website of the Alpha Omega Trial (experimental phase of Alpha Omega Cohort)</description>
  </link>
  <reference>
    <citation>Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D; Alpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010 Apr;159(4):539-546.e2. doi: 10.1016/j.ahj.2009.12.033.</citation>
    <PMID>20362710</PMID>
  </reference>
  <results_reference>
    <citation>Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010 Nov 18;363(21):2015-26. doi: 10.1056/NEJMoa1003603. Epub 2010 Aug 28.</citation>
    <PMID>20929341</PMID>
  </results_reference>
  <results_reference>
    <citation>Sijtsma FP, Soedamah-Muthu SS, de Goede J, Oude Griep LM, Geleijnse JM, Giltay EJ, de Boer MJ, Jacobs DR Jr, Kromhout D. Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the-art drug treatment. Am J Clin Nutr. 2015 Dec;102(6):1527-33. doi: 10.3945/ajcn.115.112276. Epub 2015 Oct 21.</citation>
    <PMID>26490494</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, Giltay EJ. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1676-83. doi: 10.2215/CJN.10441013. Epub 2014 Aug 7.</citation>
    <PMID>25104273</PMID>
  </results_reference>
  <results_reference>
    <citation>Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, Kromhout D; Alpha Omega Trial Group. Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline data. BMJ Open. 2012 Oct 31;2(6). pii: e001360. doi: 10.1136/bmjopen-2012-001360. Print 2012.</citation>
    <PMID>23117562</PMID>
  </results_reference>
  <results_reference>
    <citation>Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, de Goede J, Oude Griep LM, Waterham E, Teitsma-Jansen AM, Mulder BJ, de Boer MJ, Deckers JW, Zock PL, Kromhout D; for the Alpha Omega Trial Group . Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006. Neth Heart J. 2012 Feb 8. [Epub ahead of print]</citation>
    <PMID>22314614</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University</investigator_affiliation>
    <investigator_full_name>Geleijnse</investigator_full_name>
    <investigator_title>Professor of Nutrition and Cardiovascular Disease</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>mortality</keyword>
  <keyword>post-myocardial infarction patients</keyword>
  <keyword>risk prediction</keyword>
  <keyword>kidney function</keyword>
  <keyword>mental well-being</keyword>
  <keyword>cardiovascular drug treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

